Business
NXP001 agreement for pilot bioequivalence study
NXP001 agreement for pilot bioequivalence study.
About this update from Nuformix Plc
[{"type":"text","content":"\n \nRNS Number : 0126U Nuformix PLC 19 October 2017 \n\n \nNuformix plc\n(\"Nuformix\" or \"the Company\")\nNuformix signs agreement with Quotient Clinical \nto commence a pilot bioequivalence study for NXP001\n \nNuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that it has signed an agreement with Quotient Clinical ('Quotient'), a leading provider of specialist drug development services, to conduct a pilot bioequivalence study for one of Nuformix' lead programmes, NXP001, based on a currently marketed treatment in the field of oncology supportive care.\n \nPharmaceutical cocrystals are re-engineered crystalline forms of small molecule drugs, in which a drug and excipient are crystallised together. Resulting cocrystals can offer a number of performance improvements, such as solubility and dissolution of otherwise poorly soluble drugs. Under the terms of the agreement, Quotient will use its Translational Pharmaceutics platform to evaluate bioequivalence for the NXP001 cocrystal product in healthy subjects. \n \nQuotient's Translational Pharmaceutics® platform integrates formulation development and real-time adaptive GMP manufacturing with clinical research. In comparison to traditional outsourcing approaches, Quotient's Translational Pharmaceutics® platform dramatically accelerates drug product development timelines and significantly reduces development costs. Nuformix hopes to realise these benefits in its NXP001 programme, consistent with its strategy of accessing World-leading external expertise to advance key programmes.\n \nDr Dan Gooding, CEO, Nuformix plc, said: \"The appointment of Quotient was not a difficult decision as its Translational Pharmaceutics platform is perfectly suited to our needs in this final stage of our NXP001 programme - we were very impressed with Quotient's overall approach versus alternative options. Demonstrating NXP001's bioequivalence to the currently marketed product opens up immediate global out-licensing opportunities for Nuformix, so we're very excited to commence the study and also evaluate the platform's potential for future Nuformix clinical programmes,\" \n \nJohn McDermott, Executive Director, Drug Product Optimisation, Quotient Clinical, said: \"...